News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Ravi Potluri

Articles by Ravi Potluri

140 Real-World Pharmacological Management of Hyperglycemia in HR-Positive/HER2-Negative Metastatic Breast Cancer Treated With Capivasertib or Alpelisib

ByNeil M. Iyengar, MD,Ravi Potluri,Anirban Ghosh,Leah Park

May 1st 2026

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Targeting KRAS in Pancreatic Cancer: What Is Daraxonrasib’s Mechanism of Action?

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC